INSYS (INSY) Syndros Should Have Solid Uptake - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Insys Therapeutics (INSY): Syndros Approval Should Contribute $220M - RBC
July 5, 2016 8:45 AM EDTRBC Capital analyst, Randall Stanicky, noted that this morning, INSYS Therapeutics (NASDAQ: INSY) announced that it has received approval for Syndros (Dronabinol OS), its cannabinoid dronabinol oral solution. The product will be used to treat AIDS-related anorexia and nausea and vomiting in patients receiving... More
Insys Therapeutics' (INSY) Syndros Approved by FDA
July 5, 2016 6:56 AM EDTInsys Therapeutics, Inc. (Nasdaq: INSY) announced that the U.S. Food and Drug Administration (FDA) has approved Insys dronabinol oral solution, Syndros, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC"). Syndros is approved for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Syndros is currently awaiting scheduling by the U.S. Drug Enforcement Administration.
"We are very pleased... More
